[Skip to Content]
[Skip to Content Landing]
Views 210
Citations 0
Comment & Response
September 11, 2019

Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma

Author Affiliations
  • 1School of Public Health and Preventive Medicine, Monash University, Victoria, Australia
  • 2Skin and Cancer Foundation, Carlton, Victoria, Australia
  • 3Divisions of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • 4Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia
  • 5Victorian Melanoma Service, Alfred Hospital, Melbourne, Victoria, Australia
JAMA Dermatol. Published online September 11, 2019. doi:10.1001/jamadermatol.2019.2658

To the Editor We read with interest the recent article by Calomarde-Rees et al1 on risk factors for lymphatic and hematogenous dissemination in patients with stage I and II melanoma. We agree that an improved understanding of the clinicopathological and mutation factors that relate to lymphatic and hematogenous dissemination is important to individualize surveillance strategies.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×